Skip to main
GPCR

GPCR Stock Forecast & Price Target

GPCR Analyst Ratings

Based on 12 analyst ratings
Strong Buy
Strong Buy 58%
Buy 42%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Structure Therapeutics is well-positioned for future success with its promising GLP-1 drug and strong technology platform. The company's positive Phase 2 results and clear path to Phase 3 trials demonstrate its potential to outperform current options in the weight loss therapy market. While there are potential risks and challenges, the potential for significant growth and attractiveness as an acquisition target makes Structure Therapeutics a smart investment choice for those with a positive outlook.

Bears say

Structure Therapeutics is currently facing significant financial risks due to its heavy investment in research and development, with no current products on the market. Additionally, uncertainties surrounding the company's potential acquisition by larger pharmaceutical companies could lead to further instability. Furthermore, the company's focused approach on a single segment, GPCRs, may limit its potential for diversification in the future.

GPCR has been analyzed by 12 analysts, with a consensus rating of Strong Buy. 58% of analysts recommend a Strong Buy, 42% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Structure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Structure Therapeutics Inc (GPCR) Forecast

Analysts have given GPCR a Strong Buy based on their latest research and market trends.

According to 12 analysts, GPCR has a Strong Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $104.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $104.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Structure Therapeutics Inc (GPCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.